Preview

Siberian Journal of Clinical and Experimental Medicine

Advanced search

Serum levels of cardiotrophin-1 in patients with obstructive hypertrophic cardiomyopathy and in patients with severe left ventricular dysfunction

https://doi.org/10.29001/2073-8552-2021-36-2-70-75

Abstract

Relevance. Cardiotrophin-1 (CT-1) is a member of interleukin-6 (IL-6) superfamily and is associated with cardiovascular pathology. The production of CT-1 increases in response to myocardial wall stretching and increase in its rigidity and is also modulated by a wide range of neurohormones and peptides, which allows to monitor CT-1 as a marker of biomechanical stress. However, the prognostic significance of CT-1 in patients with diastolic heart failure with hypertrophic cardiomyopathy (HCM) remains poorly understood.

Objective. To study the blood serum cardiotrophin-1 contents and their relationships with NT-proBNP in patients with obstructive hypertrophic cardiomyopathy and in patients with severe left ventricular (LV) dysfunction.

Material and Methods. The study comprised a total of 76 patients with obstructive HCM and 31 patients with severe LV dysfunction. The group of patients with HCM comprised patients with obstructive form; the group of patients with severe LV dysfunction included patients with the third type of post-infarction LV remodeling and ejection fraction (EF) of less than 30%. The determination of cardiotrophin-1 and highly sensitive C-reactive protein was carried out by the enzyme immunoassay. The study of NT-proBNP content in blood serum was performed by multiplex immunoassay using the FLEXMAP 3D Luminex Corporation system.

Results. The content of cardiotrophin-1 in the blood serum of patients with obstructive HCM was higher than in the group of patients with severe LV dysfunction. The study of NT-proBNP concentrations in the blood serum showed increases in the content in both groups of patients. The median concentrations of NT-proBNP and C-reactive protein in patients with severe LV dysfunction were increased compared to the median concentration in patients with obstructive HCM.

Conclusion. The study showed an increase in cardiotrophin-1 content in the blood serum in patients with obstructive HCM with chronic diastolic heart failure. The increase in cardiotrophin-1 content was directly associated with the increase in NTproBNP level in patients with obstructive HCM with chronic diastolic heart failure.

About the Authors

O. N. Ogurkova
Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences
Russian Federation

Oksana N. Ogurkova, Cand. Sci. (Med.), Research Scientist, Clinical Diagnostic Laboratory

111a, Kievskaya str., Tomsk, 634012, Russian Federation



E. N. Pavlyukova
Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences
Russian Federation

Elena N. Pavlyukova, Dr. Sci. (Med.), Professor, Head of the Department of Atherosclerosis and Coronary Artery Disease

111a, Kievskaya str., Tomsk, 634012, Russian Federation



T. E. Suslova
Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences
Russian Federation

Tatiana E. Suslova, Cand. Sci. (Med.), Head of the Clinical Diagnostic
Laboratory

111a, Kievskaya str., Tomsk, 634012, Russian Federation



References

1. Stejskal D., Ruzicka V. Cardiotrophin-1. Review. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech. Repub. 2008;152(1):9–19. DOI: 10.5507/bp.2008.002.

2. Berezin A.E. Cardiotrophin-1 – a new prognostic marker of heart failure (literature review). Ukrainian Medical Journal. 2012;1(87):75–80 (In Russ.).

3. Martinez-Martinez E., Brugnolaro C., Ibarrola J., Ravassa S., Buonafine M., Lopez B. et al. CT-1 (Cardiotrophin-1)-Gal-3 (Galectin-3) axis in cardiac fibrosis and inflammation. Hypertension. 2019;73(3):602–611. DOI: 10.1161/HYPERTENSIONAHA.118.11874.

4. Komissarova S.S., Zakharova E.J., Rineiska N.M., Haidel I.K. Hypertrophic cardiomyopathy: Prognostic value of myocardial fibrosis volume as a predictor of chronic heart failure progression. The Siberian Journal of Clinical and Experimental Medicine.2020;35(2):75–80 (In Russ.). DOI: 10.29001/2073-8552-2020-35-2-75-80.

5. Celik A., Sahin S., Koc F., Karayakali M., Mehmet S., Benli I. et al. Cardiotrophin-1 plasma levels are increased in patients with diastolic heart failure. Med. Sci. Monit. 2012;18(1):CR25–31. DOI: 10.12659/msm.882197.

6. Latchman D.S. Cardiotrophin-1 (CT-1): A novel hypertrophic and cardioprotective agent. Int. J. Exp. Pathol.1999;80(4):189–196. DOI: 10.1046/j.1365-2613.1999.00114.x.

7. Lopez B., Gonzalez A., Querejeta R., Larman M., Rabago G., Diez J. Association of cardiotrophin-1 with myocardial fibrosis in hypertensive patients with heart failure. Hypertension. 2014;63(3):483–489. DOI: 10.1161/HYPERTENSIONAHA.113.02654.

8. Ionin V.A., Zaslavskaya E.L., Petrishcheva E.Y., Barashkova E.I., Skuridin D.S., Filatova А.G., Baranova E.I. Is cardiotrophin-1 a new risk factor of atrial fibrillation in patients with visceral obesity and metabolic syndrome? Arterial Hypertension. 2020;26(4):383–390 (In Russ.). DOI: 10.18705/1607-419X-2020-26-4-383-390.

9. Kolesnik M.Yu. The role of cardiotrophin-1 and annexin V in myocardial remodeling in spontaneously hypertensive rats with experimental diabetes mellitus. Morphologia. 2013;7(3):60–64 (In Russ.).

10. Hogas S., Bilha S.C., Branisteanu D., Hogas M., Gaipov A., Kanbay M. et al. Potential novel biomarkers of cardiovascular dysfunction and disease: Cardiotrophin-1, adipokines and galectin-3. Arch. Med. Sci. 2017;13(4):897–913. DOI: 10.5114/aoms.2016.58664.

11. Elliot P.M., Anastasakis A., Borger M.A., Borggrefe M., Cecchi F., Charron P. et al. ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur. Heart J. 2014;35(39):2733–2779. DOI: 10.1093/eurheartj/ehu284.

12. Di Donato M., Castelvecchio S., Kukulski T., Bussadori G., Giacomazzi F., Frigiola A. et al. Surgical ventricular restoration: Left ventricular shape influence on cardiac function, clinical status, and survival. Ann. Thorac. Surg. 2009;87(2):455–462. DOI: 10.1016/j.athoracsur.2008.10.071.

13. Asrih M., Mach F., Quercioli A., Dallegri F., Montecucco F. Update on the pathophysiological activities of the cardiac molecule cardiotrophin- 1 in obesity. Mediators Inflamm. 2013;2013:370715. DOI: 10.1155/2013/370715.

14. Lopez-Andres N., Inigo C., Gallego I., Dıez J., Fortuno M. Aldosterone induces cardiotrophin-1 expression in HL-1 adult cardiomyocytes. Endocrinology. 2008;149(10):4970–4978. DOI: 10.1210/en.2008-0120.

15. Zolk O., Engmann S., Munzel F., Krajcik R. Chronic cardiotrophin-1 stimulation impairs contractile function in reconstituted heart tissue. Am. J. Physiol. Endocrinol. Metab. 2005;288(6):E1214–1221. DOI: 10.1152/ajpendo.00261.2004.

16. Jougasaki M., Tachibana I., Luchner A., Leskinen H., Redfield M.M., Burnett J.C. Jr. Augmented cardiac cardiotrophin-1 in experimental congestive heart failure. Circulation. 2000;101(1):14–17. DOI: 10.1161/01.CIR.101.1.14.


Review

For citations:


Ogurkova O.N., Pavlyukova E.N., Suslova T.E. Serum levels of cardiotrophin-1 in patients with obstructive hypertrophic cardiomyopathy and in patients with severe left ventricular dysfunction. Siberian Journal of Clinical and Experimental Medicine. 2021;36(2):70-75. (In Russ.) https://doi.org/10.29001/2073-8552-2021-36-2-70-75

Views: 369


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2713-2927 (Print)
ISSN 2713-265X (Online)